Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 23, Issue 9, Pages 2313-2318
Publisher
Oxford University Press (OUP)
Online
2012-03-07
DOI
10.1093/annonc/mdr623
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
- (2010) Antoine Italiano et al. ANNALS OF SURGICAL ONCOLOGY
- Role of Src family kinases in acquired resistance to EGFR therapies in cancer
- (2010) Julie L. Boerner CANCER BIOLOGY & THERAPY
- Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab
- (2010) Deric L. Wheeler et al. CANCER BIOLOGY & THERAPY
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
- (2010) Geraldine Perkins et al. INTERNATIONAL JOURNAL OF CANCER
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Concordance ofKRAS/BRAFMutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
- (2010) S. Gattenlöhner et al. Journal of Oncology
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
- (2009) Els L. van Persijn van Meerten et al. EUROPEAN RADIOLOGY
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear EGFR contributes to acquired resistance to cetuximab
- (2009) C Li et al. ONCOGENE
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
- (2008) M. Jhawer et al. CANCER RESEARCH
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
- (2008) D. Santini et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now